Viewing Study NCT00004443



Ignite Creation Date: 2024-05-05 @ 10:22 AM
Last Modification Date: 2024-10-26 @ 9:04 AM
Study NCT ID: NCT00004443
Status: COMPLETED
Last Update Posted: 2015-03-25
First Post: 1999-10-18

Brief Title: Study of NTBC for Tyrosinemia I
Sponsor: University of Washington
Organization: FDA Office of Orphan Products Development

Study Overview

Official Title: None
Status: COMPLETED
Status Verified Date: 2000-04
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: OBJECTIVES I Assess the safety and efficacy of NTBC in children with tyrosinemia I

II Evaluate the effects of NTBC on survival rate of neurologic crises improvement in renal tubular damage reduction in the need for liver transplantation and reduction in the development of hepatocarcinoma in these patients
Detailed Description: PROTOCOL OUTLINE Patients are stratified according to age at onset of symptoms 0-2 months vs 2-6 months vs greater than 6 months

Patients receive oral NTBC twice a day Treatment continues in the absence of unacceptable toxicity

Patients are followed once a month for 6 months then every 3 months thereafter

Completion date provided represents the completion date of the grant per OOPD records

Study Oversight

Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
Secondary ID Type Domain Link
UWASH-FDR001445 None None None